Mesenchymal stem cells(Azidus Brasil)(Mesenchymal stem cells(Azidus Brasil)) - 药物靶点：NIS_在研适应症：亨廷顿舞蹈病_专利_临床

概要

基本信息

药物类型

间充质干细胞疗法

别名-

靶点

NIS

作用机制

NIS调节剂(solute carrier family 5 member 5 modulators)

治疗领域

神经系统疾病遗传病与畸形其他疾病

在研适应症

亨廷顿舞蹈病

非在研适应症-

原研机构

Azidus Brasil

在研机构

Azidus Brasil

非在研机构-

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

33

项与 Mesenchymal stem cells(Azidus Brasil) 相关的临床试验

IRCT20230222057500N1 / Recruiting临床1期IIT

Cell therapy with use of mesenchymal stem cells in infertile women with Thin Endometrium

开始日期2023-04-04

申办/合作机构

Tehran University of Medical Sciences

IRCT20230208057351N1 / Recruiting临床1期IIT

Investigating the effect of PRP and mesenchymal stem cells on improving the motor function of stroke patients

开始日期2023-02-20

申办/合作机构

Tehran University of Medical Sciences

ChiCTR2200059271 / Suspended临床1期IIT

Clinical study of high activity mesenchymal stem cells combined with microenergy in the treatment of diabetic erectile dysfunction

开始日期2022-06-01

申办/合作机构-

100 项与 Mesenchymal stem cells(Azidus Brasil) 相关的临床结果

登录后查看更多信息

100 项与 Mesenchymal stem cells(Azidus Brasil) 相关的转化医学

登录后查看更多信息

100 项与 Mesenchymal stem cells(Azidus Brasil) 相关的专利（医药）

登录后查看更多信息

38

项与 Mesenchymal stem cells(Azidus Brasil) 相关的文献（医药）

2024-02-01·Surgery

A phase IB/IIA study of ex vivo expanded allogeneic bone marrow–derived mesenchymal stem cells for the treatment of rectovaginal fistulizing Crohn’s disease

Article

作者: Pineiro, Ana Otero ; Lightner, Amy L ; VanDenBossche, Alexandra ; Adams, Ashley ; Hull, Tracy ; Reese, Jane S ; Dadgar, Neda ; Ream, Justin ; Nachand, Douglas

BACKGROUNDCrohn-related rectovaginal fistulas are notoriously difficult to treat. Studies of mesenchymal stem cells for the treatment of perianal Crohn fistulizing disease have largely excluded rectovaginal fistulas. The aim of this study was to determine the safety and efficacy of mesenchymal stem cells for refractory rectovaginal fistulizing Crohn disease.METHODSA phase IB/IIA randomized control trial was performed in a 3:1, single-blinded study. Patients included were adult women with an anovaginal/rectovaginal fistula in the setting of Crohn disease. Seventy-five million mesenchymal stem cells were administered with a 22G needle after curettage and primary closure of the fistula tract at day 0 and month 3. Adverse and serious adverse events were recorded at post-procedure day 1, week 2, week 6, month 3, month 6, and month 12, along with clinical healing, magnetic resonance imaging, and patient-reported outcomes.RESULTSA total of 19 patients were enrolled and treated-15 treatment and 4 control. There were no adverse or serious adverse events related to mesenchymal stem cell therapy. At 6 months, 50% of the treatment group and 0% of the control had complete clinical and radiographic healing; 91.7% of the treatment group had improvement at 6 months with only one patient having a lack of response, whereas only 50% of the control group had improvement at 6 months.CONCLUSIONBone marrow-derived mesenchymal stem cells offer a safe alternative treatment approach for rectovaginal fistulas in the setting of Crohn disease. Complete healing was achieved in half of the patients.

2023-12-05·Inflammatory Bowel Diseases

A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow–Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn’s Disease

Article

作者: VanDenBossche, Alexandra ; Otero-Pineiro, Ana ; Ream, Justin ; Lightner, Amy L ; Reese, Jane ; Kurowski, Jacob A ; Nachand, Douglas ; Adams, Ashley C

AbstractBackgroundPerianal fistulizing Crohn’s disease is notoriously difficult to treat. Recent studies of mesenchymal stem cells have demonstrated safety and efficacy of this novel treatment approach. However, no studies to date have included pediatric patients. We sought to determine safety and efficacy of mesenchymal stem cells for pediatric perianal fistulizing Crohn’s disease.MethodsThis was a phase I clinical trial to evaluate safety and feasibility of mesenchymal stem cells in pediatric perianal Crohn’s patients 13 to 17 years of age. At the time of an exam under anesthesia, following curettage of the fistula tract and closure of the internal opening with absorbable suture, 75 million mesenchymal stem cells were administered with a 22-gauge needle. This was repeated at 3 months if complete clinical and radiographic healing were not achieved. Adverse and serious adverse events at were measured at postprocedure day 1, week 2, week 6, month 3, month 6, and month 12. Clinical healing, radiographic healing per magnetic resonance imaging, and patient-reported outcomes were measured at the same time points.ResultsSeven pediatric patients were enrolled and treated (6 male; median age of 16.7 years). There were no adverse or serious adverse events related to the investigational product or injection procedure. At 6 months, 83% had complete clinical and radiographic healing. The perianal Crohn’s Disease Activity Index, Wexner incontinence score, and Van Assche score had all decreased at 6 months.ConclusionsBone marrow–derived mesenchymal stem cells offer a safe, and likely effective, treatment approach for pediatric perianal fistulizing Crohn’s disease.

2023-12-01·Surgical Innovation

Comments on “Mesenchymal Stem Cells versus Placebo for Perianal Fistulizing Crohn’s Disease: A Systemic Review and Meta-Analysis”

Letter

作者: Cheng, Fang

100 项与 Mesenchymal stem cells(Azidus Brasil) 相关的药物交易

登录后查看更多信息